Biocartis Group NV Logo

Biocartis Group NV

ISIN

BE0974281132

Ticker

BCART

Sector

Health Care

Sub-Industry

Health Care Services

Country

Belgium

Year Founded

2007

About Biocartis Group NV

Company Description

Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation diagnostic solutions, aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus in oncology which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for COVID-19, flu, RSV and sepsis.

Biocartis’ proprietary molecular diagnostics (MDx) IdyllaTM platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample, in virtually any setting, allowing fast and effective treatment selection and treatment progress monitoring.

Headcount

500

Served Area

Worldwide

Headquarters

Generaal De Wittelaan 11B
2800, Mechelen, Antwerpen
Belgium

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 210,517,000.00 142,480,000.00 114,277,000.00
Noncurrent Assets N/A 50,534,000.00 47,354,000.00 44,343,000.00
Property Plant And Equipment N/A 40,098,000.00 37,192,000.00 31,527,000.00
Intangible Assets Other Than Goodwill N/A 5,645,000.00 5,067,000.00 4,770,000.00
Investments In Joint Ventures N/A 2,893,000.00 2,344,000.00 2,538,000.00
Other Noncurrent Receivables N/A 426,000.00 16,000.00 N/A
Deferred Tax Assets N/A 1,472,000.00 1,595,000.00 1,664,000.00
Other Noncurrent Financial Assets N/A 0.00 1,140,000.00 N/A
Other Noncurrent Assets N/A N/A 16,000.00 204,000.00
Current Assets N/A 159,983,000.00 95,126,000.00 69,934,000.00
Inventories N/A 15,712,000.00 16,106,000.00 18,905,000.00
Current Trade Receivables N/A N/A 16,206,000.00 16,697,000.00
Other Current Receivables N/A N/A 6,556,000.00 2,236,000.00
Cash and cash equivalents 178,725,000.00 123,668,000.00 53,522,000.00 26,125,000.00
Other Current Assets N/A 3,155,000.00 2,736,000.00 5,971,000.00
Equity And Liabilities N/A 210,517,000.00 142,480,000.00 114,277,000.00
Equity 84,480,000.00 36,824,000.00 -33,897,000.00 -30,284,000.00
Issued Capital N/A -220,657,000.00 -220,657,000.00 -220,302,000.00
Retained Earnings N/A -455,343,000.00 -526,405,000.00 -443,363,000.00
Share Premium N/A 711,874,000.00 711,874,000.00 631,722,000.00
Reserve Of Sharebased Payments N/A 6,102,000.00 6,862,000.00 7,502,000.00
Equity Attributable To Owners Of Parent N/A N/A -33,897,000.00 -30,284,000.00
Noncurrent Liabilities N/A 144,248,000.00 142,672,000.00 102,112,000.00
Noncurrent Provisions N/A N/A 75,000.00 204,000.00
Noncurrent Deferred Income Including Noncurrent Contract Liabilities N/A N/A 313,000.00 149,000.00
Current Liabilities N/A 29,445,000.00 33,705,000.00 42,449,000.00
Trade And Other Current Payables To Trade Suppliers N/A N/A 11,560,000.00 11,747,000.00
Current Deferred Income Including Current Contract Liabilities N/A N/A 1,822,000.00 1,195,000.00
Other Current Liabilities N/A 7,587,000.00 8,445,000.00 8,910,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 43,128,000.00 48,269,000.00 57,481,000.00
Revenue From Sale Of Goods 31,893,000.00 40,486,000.00 45,036,000.00
Revenue From Rendering Of Services 1,246,000.00 1,730,000.00 1,377,000.00
Other Income 12,431,000.00 6,629,000.00 495,000.00
Other Expense By Nature 0.00 3,244,000.00 N/A
Profit Loss From Operating Activities -46,862,000.00 -62,645,000.00 -47,047,000.00
Finance Costs 14,569,000.00 9,488,000.00 21,179,000.00
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method -532,000.00 -659,000.00 N/A
Profit Loss Before Tax -63,162,000.00 -71,715,000.00 -65,621,000.00
Income Tax Expense Continuing Operations -228,000.00 -243,000.00 -240,000.00
Profit (loss) -62,934,000.00 -71,472,000.00 -65,381,000.00
Profit Loss Attributable To Owners Of Parent -62,934,000.00 -71,472,000.00 -65,381,000.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -62,934,000.00 -71,472,000.00 -65,381,000.00
Adjustments For Income Tax Expense N/A 228,000.00 -243,000.00 -240,000.00
Adjustments For Decrease Increase In Inventories N/A 4,042,000.00 -2,737,000.00 -5,297,000.00
Adjustments For Depreciation And Amortisation Expense N/A -9,748,000.00 9,845,000.00 10,481,000.00
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss N/A -1,698,000.00 1,362,000.00 1,178,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains N/A 1,030,000.00 1,134,000.00 N/A
Adjustments For Sharebased Payments N/A -1,432,000.00 760,000.00 640,000.00
Other Adjustments For Noncash Items N/A 80,000.00 162,000.00 N/A
Other Adjustments To Reconcile Profit Loss N/A N/A -162,000.00 -78,000.00
Cash Flows From Used In Operations N/A N/A -59,285,000.00 -38,826,000.00
Interest Paid Classified As Operating Activities N/A 7,172,000.00 6,429,000.00 6,027,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A -3,000.00 -2,000.00 N/A
Cash Flows From Used In Operating Activities N/A -39,267,000.00 -65,716,000.00 -44,855,000.00
Other Cash Payments To Acquire Interests In Joint Ventures Classified As Investing Activities N/A 1,000,000.00 0.00 1,000,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 3,005,000.00 3,686,000.00 1,569,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 15,000.00 69,000.00 368,000.00
Interest Received Classified As Investing Activities N/A 13,000.00 7,000.00 6,000.00
Cash Flows From Used In Investing Activities N/A -4,007,000.00 -3,748,000.00 -5,431,000.00
Proceeds From Borrowings Classified As Financing Activities N/A 0.00 6,000,000.00 15,000,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 7,167,000.00 7,089,000.00 26,301,000.00
Interest Paid Classified As Financing Activities N/A N/A 115,000.00 73,000.00
Other Inflows Outflows Of Cash Classified As Financing Activities N/A -50,000.00 -115,000.00 N/A
Cash Flows From Used In Financing Activities N/A -11,523,000.00 -1,204,000.00 22,463,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A -54,797,000.00 -70,668,000.00 -27,823,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -260,000.00 522,000.00 426,000.00
Cash and cash equivalents 178,725,000.00 123,668,000.00 53,522,000.00 26,125,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2021 - Q4 Dutch 🇳🇱

Insider Trades

Date Trading entity / Person Association Trade type Volume
29.04.2021 Devogelaere Benoit Executive member Buy EUR 0.00
28.04.2021 Marcofin BV Executive member Buy EUR 0.00
27.04.2021 Herman Verrelst Board Buy EUR 0.00
13.11.2020 Devogelaere Benoit Executive member Buy EUR 0.00
06.05.2020 Herman Verrelst Board Buy EUR 249,625.00
06.05.2020 Herman Verrelst Board Buy EUR 0.00
04.05.2020 Herman Verrelst Board Buy EUR 231,656.00
04.05.2020 Herman Verrelst Board Buy EUR 15,315.00
18.12.2019 Devogelaere Benoit Executive member Buy EUR 0.00
16.12.2019 Welten Ewoud Executive member Buy EUR 0.00

Short Interest


Current short interest

Position Holder Short Interest in Percent Date
Citadel Europe LLP 1.00% 18.12.20
Whitebox Advisors LLC 1.21% 16.06.23
Total 2.21%

Capital Markets Information

ISIN

BE0974281132

LEI

549300J4HOJL5KG8HY54

Listed Stock Exchange

Euronext Brussels

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.